RPR203494 | CAS#218160-26-0 | p38MAPK inhibitor

MedKoo Cat#: 406338 | Name: RPR203494

Description:

WARNING: This product is for research use only, not for human or veterinary use.

RPR203494 is a pyrimidine analogue of the p38 inhibitor RPR200765A with an improved in vitro potency.

Chemical Structure

RPR203494

CAS#218160-26-0

Theoretical Analysis

MedKoo Cat#: 406338

Name: RPR203494

CAS#: 218160-26-0

Chemical Formula: C26H29FN6O4

Exact Mass: 508.2234

Molecular Weight: 508.54

Elemental Analysis: C, 61.41; H, 5.75; F, 3.74; N, 16.53; O, 12.58

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

RPR203494; RPR203494; RPR 203494.

IUPAC/Chemical Name

((2r,5r)-2-(5-(2-(cyclopropylamino)pyrimidin-4-yl)-4-(4-fluorophenyl)-1H-imidazol-2-yl)-5-methyl-1,3-dioxan-5-yl)(morpholino)methanone

InChi Key

RERSCSYZEKLVHG-OJBMAJLDSA-N

InChi Code

InChI=1S/C26H29FN6O4/c1-26(24(34)33-10-12-35-13-11-33)14-36-23(37-15-26)22-31-20(16-2-4-17(27)5-3-16)21(32-22)19-8-9-28-25(30-19)29-18-6-7-18/h2-5,8-9,18,23H,6-7,10-15H2,1H3,(H,31,32)(H,28,29,30)/t23-,26-

SMILES Code

O=C([C@]1(C)CO[C@@H](C2=NC(C3=CC=C(F)C=C3)=C(C4=NC(NC5CC5)=NC=C4)N2)OC1)N6CCOCC6

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs

Storage Condition

0 Â– 4 oC for short term (weeks to 1 month) or -20 oC for long terms (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly.

Drug Formulation

Stock solution storage:

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 508.54 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1. Pharmaceutical compositions comprising sorafenib in combination with MAPK14 inhibitors for the treatment and prevention of liver cancer. By Zender, Lars; Rudalska, Ramona; Dauch, Daniel. From PCT Int. Appl. (2013), WO 2013007708 A1 20130117. 2. Pharmaceutical compositions comprising sorafenib in combination with MAPK14 inhibitors for the treatment and prevention of liver cancer. By Zender, Lars; Rudalska, Ramona; Dauch, Daniel. From Eur. Pat. Appl. (2013), EP 2543372 A1 20130109. 3. Compositions and methods comprising p38 MAPK inhibitors for treatment of Alzheimer's disease. By Alam, John Jahangir. From PCT Int. Appl. (2012), WO 2012154814 A1 20121115. 4. NF-κB inhibitor-p38 MAP kinase inhibitor combination for the treatment of cancer and inflammatory diseases. By Fu, Haian; Liotta, Dennis C.; Thomas, Shala L.; Snyder, James P.. From PCT Int. Appl. (2008), WO 2008150899 A1 20081211. 5. P38 alpha as a therapeutic target in bladder carcinoma. By Bernard-Pierrot, Isabelle; Radvanyi, Francois; Allory, Yves. From PCT Int. Appl. (2008), WO 2008142031 A1 20081127. ~0 Citings 6. P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation. By Bernard-Pierrot, Isabelle; Radvanyi, Francois; Allory, Yves. From Eur. Pat. Appl. (2008), EP 1992344 A1 20081119. 7. Compositions, combinations, and methods for treating cardiovascular conditions and other associated conditions. By Rudolph, Amy E.; Rocha, Ricardo; Carretero, Oscar. From U.S. Pat. Appl. Publ. (2004), US 20040167197 A1 20040826. 8. RPR203494 a pyrimidine analogue of the p38 inhibitor RPR200765A with an improved in vitro potency. By Collis, Alan J.; Foster, Martyn L.; Halley, Frank; Maslen, Christopher; McLay, Iain M.; Page, Kenneth M.; Redford, E. Jane; Souness, John E.; Wilsher, Nicola E.. From Bioorganic & Medicinal Chemistry Letters (2001), 11(5), 693-696. Language: English, Database: CAPLUS, DOI:10.1016/S0960-894X(01)00034-8 9. Preparation of imidazolyl-cyclic acetals as TNF-alpha inhibitor. By Bamborough, Paul Lindsay; Collis, Alan John; Halley, Frank; Lewis, Richard Alan; Lythgoe, David John; McKenna, Jeffrey Mark; Mclay, Iain Mcfarlane; Porter, Barry; Ratcliffe, Andrew James; Wallace, Paul Andrew. From PCT Int. Appl. (1998), WO 9856788 A1 19981217.